No actionable signal — this is standard new-hire equity compensation for a commercial-stage biotech. Monitor upcoming earnings or pipeline catalysts (revumenib, entinostat) for real share-moving events.
Price Chart
Executive Summary
Syndax granted 250,700 performance-based stock options to 8 new hires under its 2023 Inducement Plan, with four-year graded vesting. This is routine new-hire inducement equity for a commercial-stage biotech — no material financial impact.
Key Facts
- 250,700 shares of common stock granted as inducement awards to 8 new employees
- Awards are stock options under the 2023 Inducement Plan
- Vesting: 25% at one-year anniversary, then monthly over 36 months (total 4-year vest)
- Grant date: July 1, 2026; vesting commencement date and exercise price not stated
Financial Impact
Routine equity grant — no cash impact; ~0.3% dilution of ~83M basic shares outstanding (not stated, est.)
Risk Factors
- None from this filing — new-hire inducement grants are routine
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3320972 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 14, 2026 11w ago | 8-K | $24.13 $20.29 | ▼ −15.91% | ▼ −18.41% | $17.60 (−27.06%) |
Jul 1, 2026 13w ago | Press Release | $21.82 $19.48 | ▼ −10.72% | ▼ −10.31% | $17.60 (−19.34%) |
Jun 11, 2026 16w ago | Press Release | $17.91 $24.84 | ▲ +38.69% | ▲ +36.80% | $17.60 (−1.73%) |
Jun 10, 2026 16w ago | 8-K | $17.91 $24.84 | ▲ +38.69% | ▲ +36.80% | $17.60 (−1.73%) |
Jun 4, 2026 17w ago | Press Release | $17.34 $22.08 | ▲ +27.34% | ▲ +25.47% | $17.60 (+1.50%) |
Jun 4, 2026 17w ago | DEFA14A | $18.02 $21.82 | ▲ +21.09% | ▲ +22.46% | $17.60 (−2.33%) |
Jun 4, 2026 17w ago | 8-K | $18.02 $21.82 | ▲ +21.09% | ▲ +22.46% | $17.60 (−2.33%) |
Apr 30, 2026 22w ago | DEFA14A | $19.11 $18.85 | ▼ −1.36% | ▼ −6.64% | $17.60 (−7.90%) |
Apr 24, 2026 23w ago | Press Release | $21.39 $19.77 | ▼ −7.57% | ▼ −11.60% | $17.60 (−17.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access